tetano
Editor, Senior Moderator
Antiviral Res. 2017 Feb 1. pii: S0166-3542(16)30409-0. doi: 10.1016/j.antiviral.2017.01.021. [Epub ahead of print]
[h=1]Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses.[/h] Tao W[SUP]1[/SUP], Hurst B[SUP]2[/SUP], Shakya AK[SUP]1[/SUP], Uddin MJ[SUP]1[/SUP], Ingrole RS[SUP]1[/SUP], Hernandez-Sanabria M[SUP]3[/SUP], Arya R[SUP]3[/SUP], Bimler L[SUP]3[/SUP], Paust S[SUP]3[/SUP], Tarbet EB[SUP]2[/SUP], Gill HS[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The extracellular domain of influenza A ion channel membrane matrix protein 2 (M2e) is considered to be a potential candidate to develop a universal influenza A vaccine. However poor immunogenicity of M2e presents a significant roadblock. We have developed a vaccine formulation comprising of the consensus M2e peptide conjugated to gold nanoparticles (AuNPs) with CpG as a soluble adjuvant (AuNP-M2e + sCpG). We demonstrate that intranasal delivery of AuNP-M2e + sCpG in mice induces lung B cell activation and robust serum anti-M2e immunoglobulin G (IgG) response, with stimulation of both IgG1 and IgG2a subtypes. Using Madin-Darby canine kidney (MDCK) cells infected with A/California/04/2009 (H1N1pdm) pandemic strain, or A/Victoria/3/75 (H3N2), or the highly pathogenic avian influenza virus A/Vietnam/1203/2004 (H5N1) as immunosorbants we further show that the antibodies generated are also capable of binding to the homotetrameric form of M2 expressed on infected cells. Lethal challenge of vaccinated mice with A/California/04/2009 (H1N1pdm) pandemic strain, A/Victoria/3/75 (H3N2), and the highly pathogenic avian influenza virus A/Vietnam/1203/2004 (H5N1) led to 100%, 92%, and 100% protection, respectively. Overall, this study helps to lay the foundation of a potential universal influenza A vaccine.
Copyright ? 2017. Published by Elsevier B.V.
[h=4]KEYWORDS:[/h] Adjuvants; CpG; Gold nanoparticles; Influenza vaccine; Intranasal vaccination; M2e; Universal influenza vaccine
PMID: 28161578 DOI: 10.1016/j.antiviral.2017.01.021
[PubMed - as supplied by publisher]
[h=1]Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses.[/h] Tao W[SUP]1[/SUP], Hurst B[SUP]2[/SUP], Shakya AK[SUP]1[/SUP], Uddin MJ[SUP]1[/SUP], Ingrole RS[SUP]1[/SUP], Hernandez-Sanabria M[SUP]3[/SUP], Arya R[SUP]3[/SUP], Bimler L[SUP]3[/SUP], Paust S[SUP]3[/SUP], Tarbet EB[SUP]2[/SUP], Gill HS[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The extracellular domain of influenza A ion channel membrane matrix protein 2 (M2e) is considered to be a potential candidate to develop a universal influenza A vaccine. However poor immunogenicity of M2e presents a significant roadblock. We have developed a vaccine formulation comprising of the consensus M2e peptide conjugated to gold nanoparticles (AuNPs) with CpG as a soluble adjuvant (AuNP-M2e + sCpG). We demonstrate that intranasal delivery of AuNP-M2e + sCpG in mice induces lung B cell activation and robust serum anti-M2e immunoglobulin G (IgG) response, with stimulation of both IgG1 and IgG2a subtypes. Using Madin-Darby canine kidney (MDCK) cells infected with A/California/04/2009 (H1N1pdm) pandemic strain, or A/Victoria/3/75 (H3N2), or the highly pathogenic avian influenza virus A/Vietnam/1203/2004 (H5N1) as immunosorbants we further show that the antibodies generated are also capable of binding to the homotetrameric form of M2 expressed on infected cells. Lethal challenge of vaccinated mice with A/California/04/2009 (H1N1pdm) pandemic strain, A/Victoria/3/75 (H3N2), and the highly pathogenic avian influenza virus A/Vietnam/1203/2004 (H5N1) led to 100%, 92%, and 100% protection, respectively. Overall, this study helps to lay the foundation of a potential universal influenza A vaccine.
Copyright ? 2017. Published by Elsevier B.V.
[h=4]KEYWORDS:[/h] Adjuvants; CpG; Gold nanoparticles; Influenza vaccine; Intranasal vaccination; M2e; Universal influenza vaccine
PMID: 28161578 DOI: 10.1016/j.antiviral.2017.01.021
[PubMed - as supplied by publisher]